Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

roma pharmaceuticals ltd - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

Japani - englanti - すりの適正使用協議会 RAD-AR Council, Japan

nipro corporation - calcium polystyrene sulfonate - faint yellowish-white to pale yellow powdered medicine

Japani - englanti - すりの適正使用協議会 RAD-AR Council, Japan

sanwa kagaku kenkyusho co.,ltd. - calcium polystyrene sulfonate - pale yellowish white to pale yellow jelly

Japani - englanti - すりの適正使用協議会 RAD-AR Council, Japan

kyorin rimedio co.,ltd. - calcium polystyrene sulfonate - faintly yellowish white to pale yellow powder

Yhdistynyt kuningaskunta - englanti - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - calcium polystyrene sulfonate - powder for oral or rectal suspension - 999mg/1gram

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - calcium polystyrene sulphonate - powder for oral/rectal suspension - 99.934 percent weight/weight - drugs for treatment of hyperkalemia and hyperphosphatemia; polystyrene sulfonate

Yhdysvallat - englanti - NLM (National Library of Medicine)

cmp pharma, inc. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 15 g in 60 ml - sps® suspension is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates  (see precautions ).

Yhdysvallat - englanti - NLM (National Library of Medicine)

cardinal health 107, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 15 g in 60 ml - sps® suspension is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates  (see precautions ).

Yhdysvallat - englanti - NLM (National Library of Medicine)

belcher pharmaceuticals, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium cation 4.1 meq in 1 g - sodium polystyrene sulfonate for suspension is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate for suspension is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, neonates with reduced gut motility (postoperatively or drug induced) and oral administration in neonates (see precautions).